Kevin Ali 의 보수는 Organon 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$15m	US$1m	US$1b
Sep 30 2023	n/a	n/a	US$585m
Jun 30 2023	n/a	n/a	US$754m
Mar 31 2023	n/a	n/a	US$746m
Dec 31 2022	US$14m	US$1m	US$917m
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	US$19m	US$1m	US$1b

보상 대 시장: Kevin 의 총 보상 ($USD 14.83M )은 US 시장( $USD 8.45M ).

보상과 수익: Kevin 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Kevin Ali (64 yo)

3yrs

테뉴어

US$14,832,272

보상

Mr. Kevin Ali is Chief Executive Officer and Director of Organon & Co. since June 2, 2021. Mr. Ali served as the President of Global Enterprise Portfolio Strategy at Merck & Co., Inc. from 2019 to 2021 and...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kevin Ali	CEO & Director	3yrs	US$14.83m	0.053% $ 2.8m
Matthew Walsh	Executive VP & CFO	3yrs	US$5.21m	0.034% $ 1.8m
Kirke Weaver	Executive VP	1.4yrs	US$3.19m	0.011% $ 593.5k
Susanne Fiedler	Executive VP & Chief Commercial Officer	3.4yrs	US$3.84m	0.020% $ 1.0m
Joseph Morrissey	Executive VP and Head of Manufacturing & Supply	3yrs	US$3.74m	0.016% $ 831.1k
Rachel Stahler	Executive VP & Chief Information Officer	3yrs	데이터 없음	0.019% $ 981.8k
Jennifer Halchak	Head of Investor Relations	3.4yrs	데이터 없음	데이터 없음
Susan O'Neal	Chief Ethics & Compliance Officer	no data	데이터 없음	데이터 없음
Rebecca Edwards	Chief Communications Officer	no data	데이터 없음	데이터 없음
Daniel Karp	Chief Business Development Officer	no data	데이터 없음	데이터 없음
Aaron Falcione	Executive VP & Chief Human Resources Officer	3yrs	데이터 없음	0.012% $ 619.1k
Vittorio Nisita	Executive VP & Head of Global Business Services	3yrs	데이터 없음	0.0087% $ 455.3k

3.0yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: OGN 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kevin Ali	CEO & Director	3yrs	US$14.83m	0.053% $ 2.8m
Carrie Cox	Independent Chairman of the Board	3yrs	US$450.00k	데이터 없음
Robert Essner	Independent Director	3yrs	US$335.00k	데이터 없음
Rochelle Lazarus	Independent Director	3yrs	US$320.00k	0.00025% $ 13.1k
Martha McGarry	Independent Director	3yrs	US$320.00k	데이터 없음
R. Alan Ezekowitz	Independent Director	3yrs	US$330.00k	데이터 없음
Helene Gayle	Independent Director	3yrs	US$320.00k	데이터 없음
Shalini Sharp	Independent Director	3yrs	US$345.00k	0% $ 0
Philip Ozuah	Independent Director	3yrs	US$320.00k	데이터 없음
Cynthia Patton	Independent Director	3yrs	US$330.00k	데이터 없음
Grace Whiteford	Independent Director	3yrs	US$320.00k	0% $ 0
Deborah Leone	Independent Director	3yrs	US$330.00k	0% $ 0

3.0yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: OGN 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Organon 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Organon & Co., Annual General Meeting, Jun 04, 2024

CEO & Director exercised options and sold US$628k worth of stock

CEO & Director exercised options and sold US$729k worth of stock

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon Announces Two Leadership Appointments

Recent updates

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

Four Reasons Why Organon Stock Is A Good Buy

First quarter dividend of US$0.28 announced

First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Organon & Co. Provides Earnings Guidance for the Year 2023

Organon & Co., Annual General Meeting, Jun 04, 2024

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Organon & Co. to Report Q1, 2024 Results on May 02, 2024

CEO & Director exercised options and sold US$628k worth of stock

CEO & Director exercised options and sold US$729k worth of stock

Organon Stock Is Still Worth A Look

US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Fourth quarter dividend of US$0.28 announced

Full year 2023 earnings: EPS exceeds analyst expectations

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024

Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024

Investor sentiment improves as stock rises 18%

Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older

Organon: What I'm Looking For In This 8% Yield In 2024

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024

Organon: It's Darkest Before The Dawn

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 22%

Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd)

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28

Price target decreased by 13% to US$24.56

Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023

Organon: The Federal Reserve Black Swan (Rating Upgrade)

Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD)

Organon Announces First Real-World Observational Study of the JADA® System

6% Yield And Significantly Undervalued: A Closer Look At Organon

Organon Announces Two Leadership Appointments

Organon & Co. Revises Earnings Guidance for the Full Year 2023

Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar

Price target decreased by 7.8% to US$28.38

Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023

Organon & Co.: A Tough Spot To Be In Right Now

Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator

Consensus EPS estimates fall by 16%

Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023

First quarter 2023 earnings: EPS misses analyst expectations

CEO & Director exercised options and sold US$275k worth of stock

CEO & Director exercised options and sold US$160k worth of stock

Organon goes ex-dividend tomorrow

Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2022 earnings: EPS misses analyst expectations

Organon Declares Quarterly Dividend, Payable on March 16, 2023

Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023

Is There Anything Organic Or Interesting About Organon?

Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023

Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost

Organon goes ex-dividend tomorrow

Organon's (NYSE:OGN) Dividend Will Be $0.28

Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer

Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Organon & Co. Revises Earnings Guidance for the Full Year 2022

Organon: Thoughts Ahead Of Q3 Earnings

Price target decreased to US$34.50